Developer docs
API playgroundTry for free, no card

Search company profiles

BioSensics

Full company profile

uuid0002a48

Namestring
BioSensics
Legal namestring
BioSensics LLC
Websiteurl
biosensics.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

BioSensics LLC is a privately held medical device and digital health company founded in 2007 by three Harvard University scientists and headquartered in Newton, Massachusetts. The company develops FDA-listed Class II wearable sensors, including the PAMSys family (PAMSys, PAMSys ULM, PAMSys Voice, PAMSys Fall, PAMSys Gait), LEGSys, BalanSens, and BioDigit Watch, combined with a suite of digital health platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video) and a curated digital biomarker database (BioDigit Database). Its technology stack covers 3D accelerometry, IMU, audio capture, and proprietary algorithms for motion, speech, postural, gait, balance, and cognitive analysis, with ISO 13485, CE mark under MDR 2017/745, HIPAA, GDPR, and Data Privacy Framework compliance.

The company focuses on neurological, neuromuscular, autoimmune, and rare disorder indications including Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, multiple system atrophy, myasthenia gravis, hereditary ataxias, and progressive supranuclear palsy. Customers include pharmaceutical and biotech companies (25+ on BioDigit Home), academic medical centers (MGH, Johns Hopkins, Vanderbilt, Baylor, Spaulding, Beth Israel Deaconess, University of Rochester, Penn State, Kansas University), CROs, and patient advocacy organizations. Its technologies have been deployed in 100+ clinical trials and research studies across 30+ countries and 20+ languages, with 25+ trials using BioSensics products as primary or secondary endpoints and 200+ peer-reviewed publications generated from the installed base.

BioSensics monetizes through three revenue streams: hardware sales of FDA-listed wearable devices, subscription/licensing of BioDigit software platforms and database access, and professional services for clinical trial operations including study management, data quality monitoring, and technical consulting. Distribution is direct enterprise sales supported by conference-driven demand generation (AAN, MDA, DIA, CTAD, CNS Summit). R&D is heavily funded through NIH grants (over $50M cumulatively across NIA, NICHD, and other institutes), with partnerships spanning pharma (Alterity, Elpida), academic KOLs, advocacy groups (MDA, ALSA, CurePSP, AFTD, HNF, MGFA, FARA), and consortia (Digital Medicine Society).

Short descriptiontext

BioSensics develops FDA-listed wearable sensors and digital health platforms for clinical trials in neurological, neuromuscular, and rare disorders. It serves pharmaceutical companies, biotech firms, academic medical centers, and CROs across 30+ countries, with 100+ trials and 200+ publications validating its digital biomarker technologies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewton, United States
HQ citystring
Newton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable medical devices, digital biomarkers, clinical trial technology, remote patient monitoring, digital health platforms
Industry1 code
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Wearable Medical Devices and Digital Health Platforms
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Wearable Sensor Hardware Sales
TypeHardware Sales
Description

Sale of FDA-listed wearable devices including PAMSys, LEGSys, BalanSens, PAMSys ULM, and BioDigit Watch. Devices are sold as Class II medical devices with FDA listing and CE mark for use in global clinical trials.

biosensics.com
2Digital Health Platforms and Software
TypeSubscription Recurring
Description

Subscription and licensing of software platforms including BioDigit Home, BioDigit Speech, BioDigit Video, and BioDigit Database for data collection, analysis, and storage.

biosensics.com
3Clinical Trial Services
TypeProfessional Services
Description

Comprehensive technical and operational services for clinical trials including study management, data quality monitoring, technical/scientific consulting, and early phase study collaboration. Services include device logistics, site training, data management, and regulatory guidance.

biosensics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 13 records shown
1PAMSys
Description

FDA-listed wearable sensor for continuous monitoring of body postures, postural transitions, and walking parameters during activities of daily living

biosensics.com
+12 more records
Core offering1 text field

BioSensics develops and sells FDA-listed Class II wearable medical devices (PAMSys, LEGSys, BalanSens, PAMSys ULM, PAMSys Voice, BioDigit Watch) and integrated digital health software platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video, BioDigit Database) for objective measurement of motor, speech, cognitive, and behavioral symptoms in clinical trials and remote patient monitoring. The company also provides clinical trial operational and scientific services, including study management, data quality monitoring, and technical consulting. Its offerings are targeted at pharmaceutical and biotech companies, academic medical centers, and CROs conducting research in neurological, neuromuscular, autoimmune, and rare disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100+ clinical trials and research studies conducted with BioSensics technology
+4 more records
Product overview1 text field

BioSensics is a platform-plus-modules company offering end-to-end digital health solutions for clinical trials, patient monitoring, and health assessment. The core offering is built around PAMSys wearable sensors (FDA-listed Class II medical devices for continuous physical activity monitoring) combined with BioDigit digital health platforms. BioDigit Home serves as the unified remote monitoring platform integrating data from PAMSys and PAMSys ULM (upper limb monitoring), PAMSys Voice (speech monitoring), BioDigit Speech, BioDigit Video, and ePROs. The BioDigit Database provides disease-specific digital biomarker data for research access. LEGSys and BalanSens are FDA-listed gait and balance assessment devices. BioSensics also offers clinical services including study management, data quality monitoring, and technical/scientific consulting.

Product and service5 records
1PAMSys
CategoryWearable Device
Description

FDA-listed Class II wearable sensor for continuous monitoring of body postures, postural transitions, and walking parameters during activities of daily living. Measures 27 independent parameters of daily physical activity including walking/running parameters, body posture, postural transitions, activity levels, sleep quality, and fall detection. Up to 6 weeks battery life with wireless charging support. Used in clinical trials and remote patient monitoring.

2LEGSys
CategoryWearable Device
Description

FDA-listed wearable sensor system for clinical gait and balance assessments. Used in 200+ clinical studies and trials including measurement of primary endpoints in 15+ clinical trials.

3BalanSens
CategoryWearable Device
Description

FDA-listed wearable device for clinical balance assessments. Part of the first FDA-listed wearable devices for instrumented gait and balance assessments released in 2013.

4PAMSys ULM (Upper Limb Monitoring)
CategoryWearable Device
Description

Pioneering wearable sensor for continuous monitoring of upper limb health and function during everyday activities. Uses clinically validated models for goal-directed movements with hand trajectories toward specific target locations. Applied in studies for ALS, Friedreich's ataxia, myasthenia gravis, congenital myasthenic syndrome, stroke, Huntington's disease, and inclusion body myositis.

5PAMSys Voice
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership21 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Partnership to advance rare disease clinical trials combining Elpida's gene therapy expertise with BioSensics' advanced digital health platforms and wearable sensor technologies to improve trial accuracy and enhance patient experience.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on Nili care coordination platform for dementia care and digital biomarker research. Multiple NIH-funded projects including PAMSys Voice development and ADRD care management platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple collaborations including ALS digital biomarker study, myasthenia gravis pilot study (BioDigit MG), PSP longitudinal study, and FTLD syndromes research. Includes Dr. Amanda Guidon, Dr. Anne-Marie Wills.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on FTLD syndromes research including remote monitoring solutions for PSP with Dr. Alex Pantelyat, Director of Atypical Parkinsonism Center.

5Vanderbilt University Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on wearable sensors for quantitative motor assessments in multiple system atrophy with Dr. Daniel Claassen.

biosensics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on PAMSys ULM development for upper limb monitoring and StrokeWear device for stroke rehabilitation with Dr. Paolo Bonato, Director of Motion Analysis Laboratory.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner institution listed on company partnerships page.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on multi-modal remote monitoring of ALS using wearable sensors and digital assessments.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner institution listed on company partnerships page.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner institution listed on company partnerships page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership in Digital Measures Development ADRD project to expedite progress of Alzheimer's disease and related dementias research. Leverages BioDigit Database to facilitate recognition of digital biomarkers for clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-sponsor of wearable-based monitoring study for Charcot-Marie-Tooth disease actively enrolling pediatric participants ages 8-18 at HNF CMT Summit.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient advocacy group partner for muscular dystrophy research including MDA Clinical & Scientific Conference sponsorship.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with CurePSP Center of Care at Massachusetts General Hospital for progressive supranuclear palsy research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy group partner for Friedreich's ataxia research.

16ALSA (ALS Association)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy group partner for ALS research.

biosensics.com
17AFTD (Association for Frontotemporal Degeneration)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy group partner for frontotemporal degeneration research.

biosensics.com
18MGFA (Myasthenia Gravis Foundation of America)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy group partner for myasthenia gravis research.

biosensics.com
19National Institute on Aging (NIA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH institute providing grant funding for Alzheimer's disease and related dementias research including Nili platform development (~$3M grant R44AG066360) and recognition as leading digital health technology provider.

biosensics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH institute providing $3M grant for StrokeWear device development for stroke rehabilitation in collaboration with Spaulding Rehabilitation Hospital.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on use of PAMSys as secondary endpoint in Phase 2 trial in Multiple System Atrophy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ActiGraph is a leading provider of wearable activity monitors (CentrePoint series) used in clinical trials and academic research, competing directly with BioSensics' PAMSys in physical activity, sleep, and actigraphy endpoints for pharma-sponsored studies.

TypeDirect peer
Description

VivoSense develops wearable sensor analytics and digital biomarkers for clinical trials, with a focus on regulatory-grade endpoints in neurological, respiratory, and rare disease indications - directly comparable to BioSensics' BioDigit platform.

TypeDirect peer
Description

Empatica makes FDA-cleared wearable sensors (EpiMonitor, Embrace) for seizure detection and clinical research, with overlapping pharma clinical trial use cases and similar wearable-plus-algorithm digital biomarker positioning.

TypeDirect peer
Description

Koneksa Health provides digital biomarker solutions for clinical trials using wearable sensors and remote assessments in respiratory, CNS, and rare disease indications, with a similar pharma/biotech customer base and decentralized trial focus.

TypeEmerging player
Description

Aparito develops wearable and video-based digital endpoints for rare disease and oncology clinical trials, overlapping BioSensics' neurological/rare disease focus but with a narrower therapeutic footprint and emerging commercial scale.

TypeBroad incumbent
Description

Clario (formed via ERT/BIOPRO merger) is a leading clinical trial endpoint technology provider offering wearable sensors, eCOA, imaging, and cardiac safety - a much broader incumbent that competes with BioSensics in wearable clinical trial endpoints.

TypeBroad incumbent
Description

Medidata offers the Rave Clinical Cloud including eCOA, EDC, and an expanding sensor/wearable integration layer for decentralized trials, competing with BioSensics' BioDigit Home platform as part of a much wider clinical trial technology suite.

TypeBroad incumbent
Description

Verily develops wearable sensors (Verily Study Watch) and digital biomarker platforms for large-scale clinical research and pharma trials, with overlapping pursuits in objective, continuous endpoints but as part of a much broader Alphabet-backed portfolio.

TypeEmerging player
Description

Science 37 operates a decentralized clinical trial operating system that integrates remote data capture and connected devices for pharma sponsors, complementary and partially competitive with BioSensics' BioDigit Home trial platform.

TypeBroad incumbent
Description

Philips provides remote patient monitoring and clinical trial wearables/biomarker solutions through its Connected Care segment, competing with BioSensics in RPM and clinical-grade sensor deployments across hospital and pharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioSensics

Wearable Medical Devices and Digital Health Platformsbiosensics.com

BioSensics develops FDA-listed wearable sensors and digital health platforms for clinical trials in neurological, neuromuscular, and rare disorders. It serves pharmaceutical companies, biotech firms, academic medical centers, and CROs across 30+ countries, with 100+ trials and 200+ publications validating its digital biomarker technologies.

What BioSensics does

BioSensics LLC is a privately held medical device and digital health company founded in 2007 by three Harvard University scientists and headquartered in Newton, Massachusetts. The company develops FDA-listed Class II wearable sensors, including the PAMSys family (PAMSys, PAMSys ULM, PAMSys Voice, PAMSys Fall, PAMSys Gait), LEGSys, BalanSens, and BioDigit Watch, combined with a suite of digital health platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video) and a curated digital biomarker database (BioDigit Database). Its technology stack covers 3D accelerometry, IMU, audio capture, and proprietary algorithms for motion, speech, postural, gait, balance, and cognitive analysis, with ISO 13485, CE mark under MDR 2017/745, HIPAA, GDPR, and Data Privacy Framework compliance.

The company focuses on neurological, neuromuscular, autoimmune, and rare disorder indications including Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, multiple system atrophy, myasthenia gravis, hereditary ataxias, and progressive supranuclear palsy. Customers include pharmaceutical and biotech companies (25+ on BioDigit Home), academic medical centers (MGH, Johns Hopkins, Vanderbilt, Baylor, Spaulding, Beth Israel Deaconess, University of Rochester, Penn State, Kansas University), CROs, and patient advocacy organizations. Its technologies have been deployed in 100+ clinical trials and research studies across 30+ countries and 20+ languages, with 25+ trials using BioSensics products as primary or secondary endpoints and 200+ peer-reviewed publications generated from the installed base.

BioSensics monetizes through three revenue streams: hardware sales of FDA-listed wearable devices, subscription/licensing of BioDigit software platforms and database access, and professional services for clinical trial operations including study management, data quality monitoring, and technical consulting. Distribution is direct enterprise sales supported by conference-driven demand generation (AAN, MDA, DIA, CTAD, CNS Summit). R&D is heavily funded through NIH grants (over $50M cumulatively across NIA, NICHD, and other institutes), with partnerships spanning pharma (Alterity, Elpida), academic KOLs, advocacy groups (MDA, ALSA, CurePSP, AFTD, HNF, MGFA, FARA), and consortia (Digital Medicine Society).

BioSensics firmographics

Firmographics
Name
BioSensics
Legal name
BioSensics LLC
Website
https://biosensics.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
BioSensics develops FDA-listed wearable sensors and digital health platforms for clinical trials in neurological, neuromuscular, and rare disorders. It serves pharmaceutical companies, biotech firms, academic medical centers, and CROs across 30+ countries, with 100+ trials and 200+ publications validating its digital biomarker technologies.
Ownership category
akta.pro rank

BioSensics industry classification

Industry
Product category
Wearable Medical Devices and Digital Health Platforms
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Wearable medical devices
  • Digital biomarkers
  • Clinical trial technology
  • Remote patient monitoring
  • Digital health platforms

Where BioSensics is headquartered

Location

Headquarters

HQ city
Newton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioSensics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Wearable Sensor Hardware Sales: Sale of FDA-listed wearable devices including PAMSys, LEGSys, BalanSens, PAMSys ULM, and BioDigit Watch. Devices are sold as Class II medical devices with FDA listing and CE mark for use in global clinical trials.
  2. Digital Health Platforms and Software: Subscription and licensing of software platforms including BioDigit Home, BioDigit Speech, BioDigit Video, and BioDigit Database for data collection, analysis, and storage.
  3. Clinical Trial Services: Comprehensive technical and operational services for clinical trials including study management, data quality monitoring, technical/scientific consulting, and early phase study collaboration. Services include device logistics, site training, data management, and regulatory guidance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

BioSensics product offering

Product offering

Core offering

BioSensics develops and sells FDA-listed Class II wearable medical devices (PAMSys, LEGSys, BalanSens, PAMSys ULM, PAMSys Voice, BioDigit Watch) and integrated digital health software platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video, BioDigit Database) for objective measurement of motor, speech, cognitive, and behavioral symptoms in clinical trials and remote patient monitoring. The company also provides clinical trial operational and scientific services, including study management, data quality monitoring, and technical consulting. Its offerings are targeted at pharmaceutical and biotech companies, academic medical centers, and CROs conducting research in neurological, neuromuscular, autoimmune, and rare disorders.

Product overview

BioSensics is a platform-plus-modules company offering end-to-end digital health solutions for clinical trials, patient monitoring, and health assessment. The core offering is built around PAMSys wearable sensors (FDA-listed Class II medical devices for continuous physical activity monitoring) combined with BioDigit digital health platforms. BioDigit Home serves as the unified remote monitoring platform integrating data from PAMSys and PAMSys ULM (upper limb monitoring), PAMSys Voice (speech monitoring), BioDigit Speech, BioDigit Video, and ePROs. The BioDigit Database provides disease-specific digital biomarker data for research access. LEGSys and BalanSens are FDA-listed gait and balance assessment devices. BioSensics also offers clinical services including study management, data quality monitoring, and technical/scientific consulting.

Differentiator

Problem solved

Functional benefit

Brands

  • PAMSys: FDA-listed wearable sensor for continuous monitoring of body postures, postural transitions, and walking parameters during activities of daily living
  • LEGSys
  • BalanSens
  • BioDigit Watch
  • BioDigit Speech
  • BioDigit Video
  • BioDigit Home
  • BioDigit Clinic
  • BioDigit Database
  • Nili
  • StrokeWear
  • PAMSys ULM
  • PAMSys Voice

Products and services

  • PAMSys FDA-listed Class II wearable sensor for continuous monitoring of body postures, postural transitions, and walking parameters during activities of daily living. Measures 27 independent parameters of daily physical activity including walking/running parameters, body posture, postural transitions, activity levels, sleep quality, and fall detection. Up to 6 weeks battery life with wireless charging support. Used in clinical trials and remote patient monitoring.
  • LEGSys FDA-listed wearable sensor system for clinical gait and balance assessments. Used in 200+ clinical studies and trials including measurement of primary endpoints in 15+ clinical trials.
  • BalanSens FDA-listed wearable device for clinical balance assessments. Part of the first FDA-listed wearable devices for instrumented gait and balance assessments released in 2013.
  • PAMSys ULM (Upper Limb Monitoring) Pioneering wearable sensor for continuous monitoring of upper limb health and function during everyday activities. Uses clinically validated models for goal-directed movements with hand trajectories toward specific target locations. Applied in studies for ALS, Friedreich's ataxia, myasthenia gravis, congenital myasthenic syndrome, stroke, Huntington's disease, and inclusion body myositis.
  • PAMSys Voice

Quantifiable outcome

  • 100+ clinical trials and research studies conducted with BioSensics technology
  • +4 more outcomes

Companies that use BioSensics

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

BioSensics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature10 records

BioSensics partnerships and signals

Strategic signal

Partnerships

21 partnerships are on record, tiered core and minor.

  • Elpida TherapeuticscoreStrategic or Co-development Partner · 12 November 2024Partnership to advance rare disease clinical trials combining Elpida's gene therapy expertise with BioSensics' advanced digital health platforms and wearable sensor technologies to improve trial accuracy and enhance patient experience.
  • Baylor College of MedicinecoreStrategic or Co-development PartnerCollaboration on Nili care coordination platform for dementia care and digital biomarker research. Multiple NIH-funded projects including PAMSys Voice development and ADRD care management platform.
  • Massachusetts General HospitalcoreStrategic or Co-development PartnerMultiple collaborations including ALS digital biomarker study, myasthenia gravis pilot study (BioDigit MG), PSP longitudinal study, and FTLD syndromes research. Includes Dr. Amanda Guidon, Dr. Anne-Marie Wills.
  • Johns Hopkins School of MedicinecoreStrategic or Co-development PartnerCollaboration on FTLD syndromes research including remote monitoring solutions for PSP with Dr. Alex Pantelyat, Director of Atypical Parkinsonism Center.
  • Vanderbilt University Medical CentercoreStrategic or Co-development PartnerCollaboration on wearable sensors for quantitative motor assessments in multiple system atrophy with Dr. Daniel Claassen.
  • Spaulding Rehabilitation HospitalcoreStrategic or Co-development PartnerCollaboration on PAMSys ULM development for upper limb monitoring and StrokeWear device for stroke rehabilitation with Dr. Paolo Bonato, Director of Motion Analysis Laboratory.
  • University of RochesterminorStrategic or Co-development PartnerResearch partner institution listed on company partnerships page.
  • Penn State College of MedicineminorStrategic or Co-development PartnerCollaboration on multi-modal remote monitoring of ALS using wearable sensors and digital assessments.
  • Kansas University Medical CenterminorStrategic or Co-development PartnerResearch partner institution listed on company partnerships page.
  • Beth Israel Deaconess Medical CenterminorStrategic or Co-development PartnerResearch partner institution listed on company partnerships page.
  • Digital Medicine Society (DiMe)coreStrategic or Co-development PartnerPartnership in Digital Measures Development ADRD project to expedite progress of Alzheimer's disease and related dementias research. Leverages BioDigit Database to facilitate recognition of digital biomarkers for clinical trials.
  • Hereditary Neuropathy Foundation (HNF)coreStrategic or Co-development PartnerCo-sponsor of wearable-based monitoring study for Charcot-Marie-Tooth disease actively enrolling pediatric participants ages 8-18 at HNF CMT Summit.
  • MDA (Muscular Dystrophy Association)coreStrategic or Co-development PartnerPatient advocacy group partner for muscular dystrophy research including MDA Clinical & Scientific Conference sponsorship.
  • CurePSPcoreStrategic or Co-development PartnerPartnership with CurePSP Center of Care at Massachusetts General Hospital for progressive supranuclear palsy research.
  • FARA (Friedreich's Ataxia Research Alliance)minorStrategic or Co-development PartnerPatient advocacy group partner for Friedreich's ataxia research.
  • ALSA (ALS Association)minorStrategic or Co-development PartnerPatient advocacy group partner for ALS research.
  • AFTD (Association for Frontotemporal Degeneration)minorStrategic or Co-development PartnerPatient advocacy group partner for frontotemporal degeneration research.
  • MGFA (Myasthenia Gravis Foundation of America)minorStrategic or Co-development PartnerPatient advocacy group partner for myasthenia gravis research.
  • National Institute on Aging (NIA)coreStrategic or Co-development PartnerNIH institute providing grant funding for Alzheimer's disease and related dementias research including Nili platform development (~$3M grant R44AG066360) and recognition as leading digital health technology provider.
  • NICHD (Eunice Kennedy Shriver National Institute of Child Health and Human Development)coreStrategic or Co-development PartnerNIH institute providing $3M grant for StrokeWear device development for stroke rehabilitation in collaboration with Spaulding Rehabilitation Hospital.
  • Alterity TherapeuticsminorStrategic or Co-development PartnerCollaboration on use of PAMSys as secondary endpoint in Phase 2 trial in Multiple System Atrophy.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

BioSensics competitors and assessment

Company assessment

Direct peers

  • ActiGraph: ActiGraph is a leading provider of wearable activity monitors (CentrePoint series) used in clinical trials and academic research, competing directly with BioSensics' PAMSys in physical activity, sleep, and actigraphy endpoints for pharma-sponsored studies.
  • VivoSense: VivoSense develops wearable sensor analytics and digital biomarkers for clinical trials, with a focus on regulatory-grade endpoints in neurological, respiratory, and rare disease indications - directly comparable to BioSensics' BioDigit platform.
  • Empatica: Empatica makes FDA-cleared wearable sensors (EpiMonitor, Embrace) for seizure detection and clinical research, with overlapping pharma clinical trial use cases and similar wearable-plus-algorithm digital biomarker positioning.
  • Koneksa Health: Koneksa Health provides digital biomarker solutions for clinical trials using wearable sensors and remote assessments in respiratory, CNS, and rare disease indications, with a similar pharma/biotech customer base and decentralized trial focus.

Emerging players

  • Aparito: Aparito develops wearable and video-based digital endpoints for rare disease and oncology clinical trials, overlapping BioSensics' neurological/rare disease focus but with a narrower therapeutic footprint and emerging commercial scale.
  • Science 37: Science 37 operates a decentralized clinical trial operating system that integrates remote data capture and connected devices for pharma sponsors, complementary and partially competitive with BioSensics' BioDigit Home trial platform.

Broad incumbents

  • Clario: Clario (formed via ERT/BIOPRO merger) is a leading clinical trial endpoint technology provider offering wearable sensors, eCOA, imaging, and cardiac safety - a much broader incumbent that competes with BioSensics in wearable clinical trial endpoints.
  • Medidata (Dassault Systèmes): Medidata offers the Rave Clinical Cloud including eCOA, EDC, and an expanding sensor/wearable integration layer for decentralized trials, competing with BioSensics' BioDigit Home platform as part of a much wider clinical trial technology suite.
  • Verily (Alphabet): Verily develops wearable sensors (Verily Study Watch) and digital biomarker platforms for large-scale clinical research and pharma trials, with overlapping pursuits in objective, continuous endpoints but as part of a much broader Alphabet-backed portfolio.
  • Philips: Philips provides remote patient monitoring and clinical trial wearables/biomarker solutions through its Connected Care segment, competing with BioSensics in RPM and clinical-grade sensor deployments across hospital and pharma customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

BioSensics social profiles

Digital presence

BioSensics compliance and trust

Trust signal

Compliance6 records

BioSensics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioSensics leadership team

Management profile

Number of profiles

Profiles1 record

BioSensics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioSensics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSensics

What does BioSensics do?

BioSensics develops and sells FDA-listed Class II wearable medical devices (PAMSys, LEGSys, BalanSens, PAMSys ULM, PAMSys Voice, BioDigit Watch) and integrated digital health software platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video, BioDigit Database) for objective measurement of motor, speech, cognitive, and behavioral symptoms in clinical trials and remote patient monitoring. The company also provides clinical trial operational and scientific services, including study management, data quality monitoring, and technical consulting. Its offerings are targeted at pharmaceutical and biotech companies, academic medical centers, and CROs conducting research in neurological, neuromuscular, autoimmune, and rare disorders.

Is BioSensics a public or private company?

BioSensics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioSensics founded?

BioSensics was founded in 2007. It employs 11 to 50 people.

Where is BioSensics based?

BioSensics is headquartered in Newton, United States, in the North America region.

How does BioSensics make money?

Three revenue lines are on record. Wearable Sensor Hardware Sales are the primary driver. The others are digital Health Platforms and Software and clinical Trial Services.

Who are BioSensics's main competitors?

Direct peers on record are ActiGraph, VivoSense, Empatica and Koneksa Health. Emerging players are Aparito and Science 37. Broad incumbents are Clario, Medidata (Dassault Systèmes), Verily (Alphabet) and Philips.

Does BioSensics have an API?

No public API is recorded for BioSensics.

What industry is BioSensics in?

BioSensics's product category is Wearable Medical Devices and Digital Health Platforms. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialCharcot Marie Tooth Disease Clinical Trial Pipeline Gains Momentum: 13+ Companies Lead The Charge In Pioneering New Treatments DelveinsightDelveInsight released a Charcot-Marie-Tooth disease pipeline report on October 28, 2026, covering 13+ companies and 15+ pipeline drugs. It highlights a $2.2 million FDA cooperative agreement between BioSensics and CureCMT for wearable digital biomarkers, and lists emerging therapies like PXT3003 and NMD670.openPR.comDigital Biomarkers Market Transforming Healthcare Through Real-Time Data and Predictive Digital Health InnovationThe global digital biomarkers market was valued at USD 6.47 billion in 2025 and is projected to reach USD 48.97 billion by 2033, registering a CAGR of 28.8% during the forecast period (2026-2033), driven by growing demand for remote patient monitoring, widespread adoption of wearable technologies, and AI-driven digital health advancements. North America dominates the market with over 58% share, while Asia-Pacific is emerging as the fastest-growing region. Key players including BioSensics, AliveCor, Biofourmis, Fitbit, Evidation Health, Empatica, Apple Inc., and Medtronic are investing in wearable technologies and AI-driven platforms to strengthen their market presence.EIN Presswire2026 HNF CMT Summit Convenes FDA Leadership to Accelerate Rare Disease InnovationThe Hereditary Neuropathy Foundation (HNF) will host its 2026 CMT Summit + Health and Wellness Retreat at Turf Valley Resort in Maryland, convening 250–300 patients, families, clinicians, researchers, biotech/pharma leaders, and federal regulators to accelerate therapeutic progress for Charcot-Marie-Tooth disease, a rare neuromuscular disorder affecting nearly 3 million people worldwide. The summit features a session on FDA's new regulatory framework for rare diseases with participation from Dr. Janet Woodcock, former Acting FDA Commissioner and co-founder of Critical Path Institute, and Dr. Collin Hovinga, Senior VP of Rare and Orphan Disease Programs at C-Path. HNF will conduct active onsite research through its Biobank collecting biospecimens and a wearable-based monitoring study co-sponsored by BioSensics that is actively enrolling pediatric participants ages 8–18.PharmiWeb.comDigital Biomarkers Market rising at 20% CAGR with growing preventive healthcare focus by 2030The global digital biomarkers market is projected to grow at a 20% CAGR over the next five years, driven by wearable adoption, AI advances, and decentralized clinical trials. The market is segmented by product, application, therapeutic area, and end user, with key players including BioSensics, AliveCor, and Amgen.GlobeNewswireGlobal Digital Biomarkers Market Trends and Forecasts to 2035: Leading Players are AliveCor, BACtrack, Biogen, BioSensics, Empatica, Eyenuk, Feel Therapeutics, Icometrix, and QuibimThe global digital biomarkers market is projected to grow from USD 5.55 billion in 2024 to USD 35.8 billion by 2035, a CAGR of 18.5%. Wearables hold the largest product share at 50%, and monitoring is the leading purpose of solution.Chicago TribuneBest Buy holding its own, expanding tech services for seniorsBest Buy reported Q4 net income of $745 million, beating Wall Street expectations, while expanding tech services for seniors. The company acquired Critical Signal Technologies and BioSensics' predictive health business, and plans to expand curbside pickup to most stores. It expects Q1 earnings of $1 to $1.05 per share.FierceBiotechNIH grants BioSensics $2.5M+ for Huntington-monitoring wearableBioSensics received over $2.5 million in NIH funding to develop HDWear, a wearable device monitoring motor symptoms in Huntington disease patients. The device, based on its PAMSys platform, enables continuous remote monitoring of posture, gait, and falls. The two-year R&D project will also study drug response and early motor abnormalities.